IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing including drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilities meeting EMA, FDA and ANVISA standards.
We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.
IDT Biologika has laid the foundation stone for further capacities for the manufacture of active ingredients for va… https://t.co/BhOXDczrNX more info
https://t.co/8u4hWCH9cY more info
https://t.co/Pc8x8crriW more info
IDT Biologika is now using capacities at its Dessau site previously reserved for Takeda Pharmaceutical Company's de… https://t.co/NZS82Asa1C more info
As a contract manufacturer of vaccines for the worldwide protection of people against infectious diseases, we act e… https://t.co/T39lAVerfr more info
This year sees IDT Biologika celebrate its 100-year anniversary. The focus of the Bacteriological Institute of the… https://t.co/ICvWAWmaLU more info
Game changer spotted. Visual inspection activities at IDT Biologika have been made easier by setting up new inspect… https://t.co/7kX1F3DwLX more info
Vaccine manufacturer IDT Biologika will jointly invest in additional production capacities at its headquarters in D… https://t.co/5eVYvKmiSx more info
IDT Biologika received two of Outsourced Pharma and Life Science Leader’s CMO Leadership Awards 2021 in the categor… https://t.co/ImYRunraKV more info
Overall, a total of 100 million euros are currently being invested in the site... more info
Takeda provides booked capacity at the IDT site in Dessau more info
Initial data for corona vaccine indicate good tolerability but weak immune response more info
5 million vaccine doses against COVID-19 more info
IDT Biologika receives official notification of funding from the Federal government more info